mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Ipsen begins BN83495 programme

Posted on 30/11/2009 in Pharmaceutical Company Product News

Ipsen has announced the start of a trial into its investigational first-in-class steroid sulfatase (STS) inhibitor BN83495.

The drug's ability to treat advanced endometrial cancer will be examined in the controlled international, multi-centre randomised study.

BN83495 - a first-in-class orally available irreversible (STS) inhibitor - gives rise to oestrone and dehydroepiandrosterone that produce oestradiol and androstenediol that can stimulate the growth of hormone-dependent tumours.

"With further indications in breast, prostate and ovarian cancers, we believe Ipsen - with its focus on hormone-dependent cancers - will fully leverage the value of BN83495," explained Stephane Thiroloix, executive vice-president of corporate development with the organisation.

In other Ipsen news, the firm announced earlier this month that it received approval for the marketing of decapeptyl (triptorelin embonate) for the treatment of locally advanced and metastatic prostate cancer.

Authorisation was granted by the Agence Francaise de Securite Sanitaire des Produits de Sante and concerns a six-month sustained-release formulation.

Other news stories from 30/11/2009

Read more in the Zenopa News Archive

How this news is generated

Nikki
Account Manager
for this opportunity

01494 818032
(Mon to Fri 0830 to 1800 hours)
nikki@zenopa.com

Latest News

Ipsen reports strong performance in first half of 2010

Ipsen hails phase III trial performance of taspoglutide

Ipsen reports positive data from Alzheimer's trial

Ipsen receives positive EU recommendation for OBI-1

Ipsen and Roche report positive diabetes drug trial results

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use